Minnesota Oncology Hematology

Saint Paul, Minnesota 55102-2389

0 studies enrolling now · 5 studies all time

What they study most

Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Ovarian Epithelial, Fallopian Tube Adenocarcinoma, Fallopian Tube Cancer, Fallopian Tube Neoplasms, Fallopian Tube Serous Adenocarcinoma, Non-small Cell Lung Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovarian Serous Adenocarcinoma, Peritoneal Cancer

Studies at this site

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy — Running, not enrolling
• Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery — Running, not enrolling
• Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy — Completed
• Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer — Completed
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors — Completed